What is HC Wainwright’s Forecast for BDTX FY2024 Earnings?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Research analysts at HC Wainwright upped their FY2024 EPS estimates for shares of Black Diamond Therapeutics in a report released on Tuesday, November 5th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($1.29) for the year, up from their prior forecast of ($1.44). HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q4 2024 earnings at ($0.31) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.28) EPS.

A number of other brokerages have also issued reports on BDTX. Raymond James started coverage on shares of Black Diamond Therapeutics in a research report on Wednesday, July 31st. They set an “outperform” rating and a $20.00 target price on the stock. Piper Sandler boosted their price target on Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, September 23rd. Finally, Wedbush reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Black Diamond Therapeutics in a research report on Tuesday, October 8th.

Black Diamond Therapeutics Stock Up 3.5 %

NASDAQ:BDTX opened at $3.29 on Friday. Black Diamond Therapeutics has a 52-week low of $1.62 and a 52-week high of $7.66. The stock’s 50 day moving average price is $4.10 and its 200 day moving average price is $5.00. The company has a market capitalization of $186.15 million, a PE ratio of -2.47 and a beta of 2.51.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.09.

Hedge Funds Weigh In On Black Diamond Therapeutics

A number of large investors have recently modified their holdings of BDTX. Intech Investment Management LLC purchased a new position in Black Diamond Therapeutics in the third quarter worth $56,000. Vontobel Holding Ltd. acquired a new position in shares of Black Diamond Therapeutics during the 3rd quarter worth $68,000. Algert Global LLC purchased a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $133,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Black Diamond Therapeutics in the second quarter valued at about $280,000. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Black Diamond Therapeutics in the second quarter valued at about $3,029,000. 95.47% of the stock is owned by hedge funds and other institutional investors.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.